Dr. Curtis A. Lockshin is the Chief Scientific Officer at Xenetic Biosciences Inc.
As the Chief Scientific Officer of Xenetic Biosciences Inc, the total compensation of Dr Lockshin at Xenetic Biosciences Inc is $347,203. There are 2 executives at Xenetic Biosciences Inc getting paid more, with Jeffrey F. Eisenberg Esq. having the highest compensation of $446,357.
Dr Lockshin is 61, he's been the Chief Scientific Officer of Xenetic Biosciences Inc since . There are 3 older and 9 younger executives at Xenetic Biosciences Inc. The oldest executive at Xenetic Biosciences Inc is Roger Kornberg, 73, who is the Director.
Curtis's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.
xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid
Xenetic Biosciences Inc executives and other stock owners filed with the SEC include: